Prospects for CD40-directed experimental therapy of human cancer. - Test2 - elhamkhani - TriplyDB

Prospects for CD40-directed experimental therapy of human cancer.

Prospects for CD40-directed experimental therapy of human cancer.

http://www.wikidata.org/entity/Q35028895

about

Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma.A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma.CD1d activation and blockade: a new antitumor strategy Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials.Multifunctional CD40L: pro- and anti-neoplastic activity.Anti-CD40-induced inflammatory E-cadherin+ dendritic cells enhance T cell responses and antitumour immunity in murine Lewis lung carcinoma Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates.Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression Multiple myeloma: an update of developments in targeted therapy.Biochemical and molecular markers in renal cell carcinoma: an update and future prospects.Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice.Specific targeting of gene therapy to prostate cancer using a two-step transcriptional amplification system Agonistic CD40 antibodies and cancer therapy.Roadmap to a better therapeutic tumor vaccine.Target Therapy in Hematological Malignances: New Monoclonal Antibodies.The poor contribution of chimpanzee experiments to biomedical progress.Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients Anti-CD40 agonist antibodies: preclinical and clinical experience.Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo Molecular mechanism and function of CD40/CD40L engagement in the immune system.Apoptosis-Related Single Nucleotide Polymorphisms and the Risk of Non-Small Cell Lung Cancer in Women.Unravelling the complexity of cancer-immune system interplay.Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.Critical role of CD40-mediated autocrine tumor necrosis factor-alpha in potentiation of cisplatin-induced cytotoxicity in cancer cells.Recombinant monomeric CD40 ligand for delivering polymer particles to dendritic cells.Influence of sCD40L on gastric cancer cell lines.TRAF6 is required for TRAF2-dependent CD40 signal transduction in nonhemopoietic cells Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas.Development and Validation of a Quasi-Quantitative Bioassay for Neutralizing Antibodies Against CP-870,893.CD40 induces antigen transporter and immunoproteasome gene expression in carcinomas via the coordinated action of NF-kappaB and of NF-kappaB-mediated de novo synthesis of IRF-1.Increased pressure stimulates aberrant dendritic cell maturation.A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation.Gene transfer of pro-IL-18 and IL-1beta converting enzyme cDNA induces potent antitumor effects in L1210 cells.Increased extracellular pressure provides a novel adjuvant stimulus for enhancement of conventional dendritic cell maturation strategies.Immunotherapy for B-Cell Neoplasms using T Cells expressing Chimeric Antigen Receptors: From antigen choice to clinical implementation.Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma.New frontiers for platelet CD154.Immune properties of recombinant vaccinia virus encoding CD154 (CD40L) are determined by expression of virally encoded CD40L and the presence of CD40L protein in viral particles.

P2860

Q26779221-69CD5D45-8374-4C53-B28C-9CE2DECD8F7E Q33402203-F6ECE0CC-7CF2-4C53-B2D4-3DE30DB823F2 Q33415880-193A6B86-9802-444A-93FA-DFEF0EB58D9E Q33829132-98A5F925-A3D9-4D52-8C43-DEBE3FE5CDEE Q34257902-421FAB14-7383-4DEB-B3AF-3DD0288F279B Q34405616-A578A80A-2CC7-4C30-AA78-F551B712024E Q34422566-BDB21111-0C4E-40FA-83B2-A218CEDA68A8 Q35068131-D2628F2D-C3CF-4213-9A93-C0D80705F1C1 Q35546416-7EDEB71E-FFEC-4723-9606-A8191891B039 Q35800342-3E5E8906-52E4-4FD9-B46F-21205A226706 Q36118436-3CA73B77-7C4A-495A-92D4-E886739D680E Q36271231-106C8E15-DB68-4242-8622-A3F5C7198456 Q36465489-0C30FAC4-1C66-4418-905E-EAC190478771 Q36512533-6EB09107-D19C-4CF0-A711-5ABDA5A8F318 Q36664195-C3C26913-2782-469B-9826-FDC378492C6B Q36684496-60453099-CEBD-4473-B6B3-74463D83109C Q36979140-2C0D285E-2984-4052-95FC-DF9782205DDB Q36985853-65F1B170-1ACB-42F2-A6C6-3C1E79C0B239 Q37174695-27650D9B-1F3F-4C60-A085-19E659CF8EA2 Q37252440-F63D8359-1D34-46A5-87E0-E6467082C27A Q37386167-A03CBB2D-6665-430E-8659-6963499CC917 Q37474929-5B1D887C-4090-41CA-8D3A-3A568192B5C0 Q37727768-BBE02375-86CE-4F55-9063-503D480ACCBD Q37765590-26B4A34E-8B31-44BF-A7C2-0CEE7F8E385E Q39190801-86D58D41-D899-4306-8546-67FEF3512151 Q39456061-532BDB1D-E558-4C32-A202-5373775B858F Q39549087-F7AB1A58-8EBD-4C1B-8E4B-2433E610C64B Q39572706-A000B67C-4A75-414B-8BE3-1958D830B398 Q39613693-14CD5AC0-471F-46EC-8BB9-74AB78F77219 Q39848254-F69244F4-8504-4F42-AF38-4AFCD1EC1101 Q39923907-BBAF21AE-C099-42F2-AFC7-C07CFF971524 Q39951749-171B0964-564E-4E0E-B003-4846BE04F337 Q40030490-C2E59346-3BC3-4E6B-AADD-5CB44C9853CF Q40326255-F92F2C43-2B19-4294-9B71-AF3216242B16 Q40584420-0C02309D-355E-4449-A58F-73D91CEB4F43 Q42261479-FB0C4D15-5B7D-43E5-B0F1-04A5EF03A002 Q42427577-65FB880C-7846-4111-AD9A-EF76042F8898 Q42798836-9474FA20-393D-4425-A9C4-E1AB6AA16762 Q43182095-CA68D32B-7949-4FCF-AA86-A384D99B34CA Q45590933-4C634D88-391D-4F82-AE3D-BBE583881E3C

P2860

Prospects for CD40-directed experimental therapy of human cancer.

http://www.wikidata.org/entity/Q35028895

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Prospects for CD40-directed experimental therapy of human cancer.

@ast

Prospects for CD40-directed experimental therapy of human cancer.

@en

type

label

Prospects for CD40-directed experimental therapy of human cancer.

@ast

Prospects for CD40-directed experimental therapy of human cancer.

@en

prefLabel

Prospects for CD40-directed experimental therapy of human cancer.

@ast

Prospects for CD40-directed experimental therapy of human cancer.

@en

P1433

Q35028895-8D82A909-8756-4A48-BB4D-519883DB8D4B

P1476

Q35028895-73A1F6ED-13EC-4A9B-9360-2F8C01C77976

P2093

Q35028895-024A6E3D-9309-42F1-A30B-9F1F8ACEE602

Q35028895-CAE3AA8A-463E-470A-99CD-6678EA222822

P2860

Q35028895-03ACF2DA-A930-423D-892B-102D47959583

Q35028895-0486C295-1614-485A-89DD-9583E4C37830

Q35028895-08DB1230-9B7F-48C6-8321-DF6EFEEB43B1

Q35028895-0AFA5A6D-74AF-4724-8C53-9AA83D9F17EB

Q35028895-0E4483AF-27E0-4CE3-8B81-F7101A39A242

Q35028895-0EB36545-8B4E-40AC-ACF4-8D9F9D7B89CF

Q35028895-110FFE44-8FAA-4A10-A9A3-EACD77480A09

Q35028895-14533C60-0C34-4118-AFA7-E8816425FD4E

Q35028895-172C2EB6-455E-48F6-A719-54CE7EABDBF0

Q35028895-177E97E8-F469-40F6-B176-F0AF68612008

P2888

Q35028895-495B3FC4-0374-4232-A24C-2FF35B2FCAB3

P304

Q35028895-FEFA2FF8-DF36-4AA3-AA35-70D6DCBB0F03

P31

Q35028895-9F8CD294-F86C-45A9-9618-9463C01BFFA3

P356

Q35028895-BDE33CF5-961D-4A61-9353-98C0466BCA1C

P433

Q35028895-299EABDC-1ED8-49B9-9A92-4B43A5B841DE

P478

Q35028895-A2068DF6-169F-429F-A79C-3C407D991D59

P577

Q35028895-CA59EFCF-9C2A-4FE6-804C-1AB4D800F4AE

P5875

Q35028895-AB5F632F-D71B-4406-86FE-A1562E01E8C0

P698

Q35028895-6826F468-9C98-4BA4-B5A8-6F0DD22EE5B8

P356

P1433

Cancer Gene Therapy

P1476

Prospects for CD40-directed experimental therapy of human cancer.

@en

P2093

Alex W Tong

http://www.w3.org/2001/XMLSchema#string

Marvin J Stone

http://www.w3.org/2001/XMLSchema#string

P2860

CD40 AND CD154 IN CELL-MEDIATED IMMUNITY

Human CD40-ligand: molecular cloning, cellular distribution and regulation of expression by factors controlling IgE production

TRAF5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling

Molecular basis for CD40 signaling mediated by TRAF3

Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation

The CD40/CD154 receptor/ligand dyad

Chemoattractants MDC and TARC are secreted by malignant B-cell precursors following CD40 ligation and support the migration of leukemia-specific T cells

Signaling lymphocytic activation molecule is expressed on CD40 ligand-activated dendritic cells and directly augments production of inflammatory cytokines

Molecular characterization of CD40 signaling intermediates

The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily

P2888

P304

1-13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.CGT.7700527

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2003-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6276564

http://www.w3.org/2001/XMLSchema#string

P698

12489023

http://www.w3.org/2001/XMLSchema#string